Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. develops novel biologic antibody programs for inflammatory and immunology diseases, with disclosed focus areas including atopic dermatitis, asthma, eosinophilic esophagitis and chronic obstructive pulmonary disease. Its programs target established mechanisms of action and use antibody engineering intended to optimize half-life and dosing properties.
Recurring APGE news includes clinical data and pipeline updates for zumilokibart (APG777), APG279, which combines zumilokibart with APG990, and APG333. Company updates also cover operating and financial results, public equity offerings, management conference participation, shareholder-voting matters, governance changes and financing activity to support preclinical studies, clinical trials, manufacturing, commercial readiness and general corporate purposes.
Apogee Therapeutics (Nasdaq: APGE) has announced its inaugural virtual R&D Day, scheduled for December 2, 2024, at 10:00 a.m. ET. The event will showcase the company's progress in developing novel biologics for inflammatory and immunology (I&I) conditions, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
The presentation will feature management updates focusing on APG777's potential in atopic dermatitis treatment, combination therapy strategies, and commercial opportunities in I&I markets. Key opinion leaders will discuss the current treatment landscape and emerging opportunities for patients with these conditions.
Apogee Therapeutics (APGE) reported Q3 2024 financial results and pipeline updates. The company highlighted positive 9-month results from APG777's Phase 1 trial, supporting its potential best-in-class profile with a 75-day half-life. Key financial metrics include $753.8M in cash providing runway into 2028, R&D expenses of $45.7M, and a net loss of $49.0M. The company is advancing multiple clinical programs, including APG777 (Phase 2 data expected 2H 2025), APG808 (Phase 1 interim data in Q4 2024), and APG990 (Phase 1 interim data in 1H 2025). Additionally, APG333 was selected as a development candidate with Phase 1 initiation planned for late 2024 or early 2025.
Apogee Therapeutics (APGE), a clinical-stage biotech company focused on inflammatory and immunology treatments, announces its participation in three major investor conferences this November. The company will present at the Guggenheim Inaugural Healthcare Innovation Conference on November 12 at 3:00 p.m. ET, the Stifel 2024 Healthcare Conference on November 18 at 10:20 a.m. ET, and the Jefferies London Healthcare Conference on November 20 at 10:30 a.m. ET. Live and archived webcasts will be accessible through Apogee's website investor section.
Apogee Therapeutics (APGE) announced updated positive results from its Phase 1 trial of APG777, a novel anti-IL-13 antibody for atopic dermatitis treatment. The trial demonstrated a well-tolerated safety profile with doses up to 1,200mg, showing a half-life of approximately 75 days - three to five times longer than current treatments. Key findings include dose-proportional pharmacokinetics, near-complete inhibition of pSTAT6, and sustained TARC inhibition up to 9 months. The company expects to report Phase 2 proof-of-concept data in 2H 2025, with potential for maintenance dosing every 3-6 months compared to current biweekly or monthly treatments.
Apogee Therapeutics (Nasdaq: APGE) has announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting in Boston from October 24-28, 2024. The presentation will showcase data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for treating atopic dermatitis and other inflammatory diseases.
The poster, titled "APG777, anti-IL-13 monoclonal antibody, demonstrates extended half-life and sustained inhibition of Type 2 inflammatory biomarkers," will be presented on Friday, October 25, from 2:00-6:00 p.m. ET at the Hynes Convention Center. The presentation will be available on Apogee's website on October 24.
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotechnology company, has announced its participation in the Stifel 2024 Immunology and Inflammation Summit. The company's management will engage in a fireside chat on September 18, 2024, at 12:30 p.m. E.T. / 9:30 a.m. P.T.
Apogee specializes in developing novel biologics for major inflammatory and immunology (I&I) markets, focusing on treatments for atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and other I&I indications. Their approach aims to offer potentially differentiated efficacy and dosing options.
Interested parties can access a live and archived webcast of the presentation through the News & Events page in the Investors section of Apogee Therapeutics' website.
Apogee Therapeutics (Nasdaq: APGE) has appointed Jeff S. Hartness as Chief Commercial Officer. With over 25 years of biotech industry experience, Hartness brings extensive expertise in product launches, market access strategy, pricing, and policy. He joins from Bausch Health, where he most recently served as Executive Vice President on the Global Executive Leadership Team. Prior to that, he spent 15 years at Sanofi Pharmaceuticals focused on market access and launch execution.
CEO Michael Henderson highlighted Hartness's experience in leading launch strategies for major portfolios and navigating both emerging and established markets. Hartness expressed enthusiasm for Apogee's potential to address unmet needs in inflammatory and immunology conditions, particularly in atopic dermatitis and other I&I diseases.
Apogee Therapeutics (Nasdaq: APGE) has initiated dosing in its Phase 1 clinical trial for APG990, a novel half-life extended monoclonal antibody targeting OX40L for atopic dermatitis (AD) treatment. The trial, involving healthy volunteers, will assess safety, tolerability, and pharmacokinetics. Interim data is expected in 2025.
Apogee plans to start a combination trial of APG777 and APG990 in 2025, potentially offering enhanced efficacy in AD and other inflammatory and immunology (I&I) diseases. This approach combines IL-13 inhibition (APG777) with OX40L inhibition (APG990), targeting multiple inflammation pathways.
The company has advanced three programs to clinical trials within 12 months, demonstrating rapid progress in developing differentiated treatments for major I&I diseases.
Apogee Therapeutics (Nasdaq: APGE) reported pipeline progress and Q2 2024 financial results. Key highlights include:
1. Advancement of APG777 with Phase 2 Part A data expected in 2H 2025
2. APG808 interim Phase 1 data due in Q4 2024
3. APG990 Phase 1 trial initiation accelerated to Q3 2024
4. Addition of APG333, targeting TSLP, to enter clinic in 2025
5. Planned combination studies of APG777+APG990 and APG777+APG333
Financial position: $790 million in cash, cash equivalents, and marketable securities, providing runway into 2028. Q2 2024 R&D expenses were $33.2 million, G&A expenses $10.9 million, and net loss $33.8 million.
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotechnology company, announced the appointment of Lisa Bollinger, MD, to its board of directors. Dr. Bollinger, with over 30 years of experience in drug development and regulatory affairs, previously served as VP, Global Regulatory Affairs and Clinical Safety at Merck. She brings extensive expertise in pediatrics and regulatory processes, having held significant roles at the FDA and Amgen. Apogee CEO Michael Henderson emphasized her role in advancing the company's pipeline, including treatments for atopic dermatitis and COPD. Dr. Bollinger expressed enthusiasm for contributing to Apogee's mission to develop innovative therapies for diseases with high unmet needs.